Ulcerative Colitis Clinical Trial
Official title:
Observation of the Effect of Vitamin D Supplementation on Chronic Course of Patients With Ulcerative Colitis Based on Vitamin D Receptor Fok I Gene Polymorphism,a Prospective Cohort Study
Aims:Prospectively observe the effects of Vitamin D drops supplementation on the chronic
course of ulcerative colitis patients, analyze whether the effect of Vitamin D drops on UC
patients is affected by factors such as disease site, disease activity, treatment,
etc.Exploring the relationship between Fok I gene polymorphism and the efficacy of vitamin D
supplementation. Provide a certain theoretical basis for "precision treatment" for UC
patients in the future.
Design：It is a prospective cohort study. Investigators include a total of 100 participants
with UC according to the inclusion and exclusion criteria, and divide them into two groups to
assess their initial disease activity and detect related indicators. At the same
time，investigators detect the Fok I gene polymorphism in all participants.One group is given
Vitamin D drops 400IU per day orally, and the control group do not intervene. Participants'
disease activity is assessed at baseline and related indicators are determined. The disease
activity is re-evaluated in the 3rd, 6th, 9th, and 12th months, and the serum indexes are
re-evaluated.Investigators use statistical methods to analyze whether Vitamin D drops
supplementation treatment can increase the serum 25 (OH) D level of UC participants, improve
the condition of UC participants,relationship with Fok I gene polymorphism，and analyze the
effects of Vitamin D drops on participants with UC is affected by factors such as disease
site, disease activity, and treatment.
1. The research can be started only after approval by the Medical Ethics Committee of the
Second Affiliated Hospital of Wenzhou Medical University.
2. According to the "Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease"
formulated by the Beijing Conference in 2018 as a standard, patients with clear
diagnosis of UC are collected.Other diagnostic criteria include Vitamin D deficiency (<=
20ng / ml). Exclusion criteria included pregnancy, breastfeeding, liver and kidney
dysfunction, concurrent autoimmune diseases, and use of antiepileptic drugs or drugs
metabolized by liver cytochrome P450 enzymes.
3. Assess disease activity of UC participants based on the "Moya score".
4. General information about participants with UC is collected.
5. Detection of Fok I gene polymorphism using Snapshot technology.
6. The level of serum 25 (OH) D of participants is detected.
7. Serum C-reactive protein, erythrocyte sedimentation rate, albumin, calcium and
phosphorus levels are measured.
8. Develop a treatment plan for all participants.
9. Participants are divided into two groups, one group is given oral Vitamin D drops 400IU/
d, and the other group do not intervene.
10. The disease activity is re-evaluated in the 3rd, 6th, 9th, and 12th months, and the
above serum indexes are re-evaluated.
11. Follow-up for 12 months. By comparing the above indicators, observe that in the Han
population:
1. Can Vitamin D drops supplementation increase serum 25 (OH) D levels in patients
with UC?
2. Can Vitamin D drops supplementation improve the condition of patients with UC?
3. Whether Fok I gene polymorphism affect the efficacy of Vitamin D drops
supplementation therapy?
4. Whether the effects of Vitamin D drops on UC patients is affected by factors such
as disease site, disease activity, treatment, etc ..
12. Through statistical analysis, comprehensive analysis of the effectiveness and safety of
Vitamin D drops supplementation in Han patients with UC, and its relationship with Fok I
gene polymorphism, providing a theoretical basis for further "precise treatment"
intervention in inflammatory bowel disease.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
| Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
| Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
| Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
| Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
| Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
| Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
| Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
| Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
| Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
| Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
| Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
| Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
| Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
| Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
| Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |